Drug labels would have to show where medications and ingredients were made

What does this do?

HR 8269 would require prescription and over-the-counter drug labels to identify the original manufacturer of each active ingredient, the manufacturer of the finished drug product, and any packer or distributor involved. This information could appear directly on the label or be accessible through a barcode or QR code linked to an online database. Manufacturers would also have to provide this information in paper form upon request, and companies would have at least one year after FDA finalizes its rules to comply.

Who does it affect?

The bill affects drug manufacturers, packagers, and distributors that sell medications in the United States, including companies that source ingredients from overseas. Consumers and pharmacists would also be affected, gaining easier access to information about where a drug and its ingredients were produced.

Why does it matter?

People who want to know whether drug ingredients come from specific countries, such as China or India, where a large share of pharmaceutical ingredients are currently manufactured, would have a clearer way to find that information. The bill also exempts finished drug products that meet the new labeling requirements from a separate customs marking rule, since the drug label would already carry the required location information.

Where does it stand?